Preview

Obstetrics, Gynecology and Reproduction

Advanced search

Prevention of recurrent fetal growth retardation in patients with circulating antiphospholipid antibodies and genetic thrombophilia

https://doi.org/10.17749/2313-7347/ob.gyn.rep.2022.309

Abstract

Aim: to evaluate the effectiveness of using low molecular weight heparin (LMWH) and low-dose acetylsalicylic acid (ASA) in preventing recurrence of early and late fetal growth retardation (FGR) in patients with antiphospholipid syndrome (APS) and/or genetic thrombophilia.

Materials and Methods. A prospective randomized controlled study was conducted by examining 32 patients aged 23 to 43 years with a history of early and late II and III FGR as well as thrombophilia. Prevention protocol using LMWH and ASA was carried out from the pregravid period or early pregnancy. The control group included 35 women with uncomplicated pregnancy. Antiphospholipid antibodies (APA) were measured according to the Sydney antiphospholipid syndrome (APS) criteria by using enzyme immunoassay (ELISA): cardiolipin, β2-glycoprotein 1 and additionally antibodies to annexin V, prothrombin, etc. (IgG/IgM isotypes); lupus anticoagulant – by a three-stage method with Russell's viper venom; antithrombin III and protein C levels – by chromogenic method; prothrombin gene polymorphisms G20210A as well as factor V Leiden polymorphism – by chain reaction; homocysteine – by ELISA.

Results. It was found that prevention protocol was effective in 78.1 % cases. FGR re-developed in 7 (21.9 %) pregnant women: in 2 (6.3 %) at 20 and 22 weeks, in 3 (9.4 %) at 30–32 weeks, in 2 (6.3 %) after 34 weeks of pregnancy. All these patients were found to have APA exceeding 40 U/ml with low dynamics of decline, 3 (9.4 %) were older than 35 years, 2 (6.3 %) had chronic kidney pathology and 1 (3.1 %) had a hypertension in the anamnesis.

Conclusion. The use of LMWH and low-dose ASA starting from the pre-pregnancy period and early pregnancy as a part of complex therapy allows to effectively prevent re-development of FGR in patients with thrombophilia. In case of high APA titers, the use of LMWH and low-dose ASA may be ineffective, and alternative treatment methods in addition to anticoagulant therapy should be used to improve obstetric results.

About the Authors

E. A. Orudzhova
Maternity Hospital № 1 – Branch of Vorokhobov City Clinical Hospital № 67
Russian Federation

MD, Head of Antenatal Outpatient Care Center

Moscow Healthcare Department; 2/44 Salyama Adilya Str., Moscow 123423, Russia



V. O. Bitsadze
Sechenov University
Russian Federation

MD, Dr Sci Med, Professor of RAS, Professor, Department of Obstetrics and Gynecology, Filatov Clinical Institute of Children’s Health

Scopus Author ID: 6506003478. Researcher ID: F-8409-2017

2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow 119991, Russia



M. V. Tretyakova
Sechenov University
Russian Federation

MD, PhD, Obstetrician-Gynecologist, Assistant, Department of Obstetrics and Gynecology, Filatov Clinical Institute of Children’s Health

2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow 119991, Russia



D. A. Doronicheva
Sechenov University
Russian Federation

MD, Clinical Resident, Department of Obstetrics and Gynecology, Filatov Clinical Institute of Children’s Health

2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow 119991, Russia



F. Yakubova
Sechenov University
Russian Federation

MD, Clinical Resident, Department of Obstetrics and Gynecology, Filatov Clinical Institute of Children’s Health

2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow 119991, Russia



References

1. Brosens I., Pijnenborg R., Vercruysse L., Romero R. The "Great Obstetrical Syndromes" are associated with disorders of deep placentation. Am J Obstet Gynecol. 2011;204(3):193–201. https://doi.org/10.1016/j.ajog.2010.08.009.

2. Gardosi J., Madurasinghe V., Williams M. et al. Maternal and fetal risk factors for stillbirth:populationbasedstudy. BMJ. 2013;346:f108. https://doi.org/10.1136/bmj.f108.

3. Malacova E., Regan A., Nassar N. et al. Risk of stillbirth, preterm delivery, and fetal growth restriction following exposure in a previous birth: systematic review and meta-analysis. BJOG. 2018;125(2):183–92. https://doi.org/10.1111/1471-0528.14906.

4. Abou-Nassar K., Carrier M., Ramsay Т., Rodger М.А. The association between antiphospholipid antibodies and placenta-mediated complications: а systematic review and meta-analysis. Thromb Res. 2011;128(1):77–85. https://doi.org/10.1016/j.thromres.2011.02.006.

5. Gris J.-K., Makatsariya A.D., Bitsadze V.O. et al. Antiphospholipid syndrome and pregnancy. [Antifosfolipidnyj sindrom i beremennost']. Akusherstvo i ginekologiya. 2018;(10):5–11. (In Russ.). https://doi.org/10.18565/aig.2018.10.5-11.

6. Saccone G., Berghella V., Maruotti G.M. et al. Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study. Am J Obstet Gynecol. 2017;216(5):525.e1–525.e12. https://doi.org/10.1016/j.ajog.2017.01.026.

7. Polzin W.J., Kopelman J.N., Robinson R.D. et al. The association of antiphospholipid antibodies with pregnancies complicated by fetal growth restriction. Obstet Gynecol. 1991;78(6):1108–11.

8. Schjetlein R., Moe N., Wisloff F. et al. Preeclampsia and fetal growth retardation: is there an association with antiphospholipid antibodies? Hypertension in Pregnancy. 2009;17(1):81–92. https://doi.org/10.3109/10641959809072240.

9. Spegiorin L.C.J.F., Galão E.A., De Godoy J.M.P. et al. Antiphospholipid antibodies and growth retardation in intrauterine development. Prague Med Rep. 2007;108(2):185–90.

10. Orudzhova E.A. Antiphospholipid antibodies, genetic thrombophilia and fetal growth retardation. [Antifosfolipidnye antitela, geneticheskaya trombofiliya i zaderzhka rosta ploda]. Obstetrics, Gynecology and Reproduction. 2021;15(6):695–704. (In Russ.). https://doi.org/10.17749/2313-7347/ob.gyn.rep.2021.278.

11. Heilmann L., von Tempelhoff G.-F., Pollow K. Antiphospholipid syndrome in obstetrics. Clin Appl Thromb Hemost. 2002;9(2):143–50. https://doi.org/10.1177/107602960300900209.


Review

For citations:


Orudzhova E.A., Bitsadze V.O., Tretyakova M.V., Doronicheva D.A., Yakubova F. Prevention of recurrent fetal growth retardation in patients with circulating antiphospholipid antibodies and genetic thrombophilia. Obstetrics, Gynecology and Reproduction. 2022;16(2):134-142. (In Russ.) https://doi.org/10.17749/2313-7347/ob.gyn.rep.2022.309

Views: 1517


ISSN 2313-7347 (Print)
ISSN 2500-3194 (Online)